Tools chosen: kalshi_direct claude_news gdelt_news kalshi_related polymarket_related congress_bills

Sub-questions (Fermi decomposition)

Planner reasoning

This is a long-horizon policy question about whether Trump's administration will take action eliminating the cost of at least one IVF cycle before Jan 2029. The key drivers are the status of Trump's executive order on IVF, any concrete federal action mandating free/no-cost IVF coverage, and the political/legal feasibility. Market price is the primary anchor.

# Current state The resolution criterion requires the President to take an action that **eliminates the cost** of at least one IVF cycle before Jan 20, 2029. As of late July 2026, the Trump administration has taken incremental cost-reduction steps (drug discounts, employer benefit pathways) that fall well short of eliminating costs. # Timeline of key events - **2024 campaign**: Trump pledges to make IVF free [claude_news, confirmed] - **2025-02-18**: Trump signs EO directing policy recommendations on IVF access/cost reduction; no new rights or guarantees established [AJMC, confirmed] - **2025-04-01**: IVF for Military Families Act introduced (Duckworth/Jacobs); referred to committee [congress.gov, confirmed] - **2025-05-19**: Health Coverage for IVF Act of 2025 (Underwood) referred to House committee [congress.gov, confirmed] - **2025-05-20**: EO's 90-day policy recommendation deadline passes with no White House action [reproductivefreedom.house.gov, confirmed] - **2025-10-16**: White House announces 84% drug discount via EMD Serono deal on TrumpRx portal + employer benefit pathway guidance [Axios, confirmed] - **2026-02-05**: TrumpRx.gov launches with fertility medication discounts [Prelude Fertility, confirmed] - **2026-05-11**: Trump Admin proposes new IVF employer benefit expansion [Benzinga, confirmed] - **2026-05-21**: CNN reports IVF costs "still a long way off" from Trump's promises [CNN, confirmed] - **2026-07-21**: Senator blasts GOP for killing IVF for soldiers; Catholic Bishops ask Trump to change IVF insurance rule [alternet, Newsweek, confirmed] --- # Event Will Trump take action eliminating the cost of at least one IVF cycle before Jan 20, 2029? # Outcomes to forecast - **Yes**: President takes action eliminating cost of ≥1 IVF cycle before Jan 20, 2029 - **No**: No such action taken # Kalshi market anchor **Current YES price: 13%** | 7-day change: 0% | 30-day change: −3% | Avg daily volume: 32 contracts | Range over 63 days: 13–17%. Market has drifted down and stabilized at 13%. # Sub-question answers 1. **Current Kalshi price?** — 13% YES, stable for 7 days, down 3% over 30 days [kalshi_direct] 2. **Executive actions on IVF affordability?** — Feb 2025 EO (recommendations only); Oct 2025 drug discount deal (84% off select meds via TrumpRx); employer benefit pathway guidance; TrumpRx.gov launched Feb 2026 [claude_news, AJMC, Axios] 3. **Concrete federal policy eliminating IVF cost?** — No. All actions are discounts or voluntary employer incentives; no mandate or program eliminating cycle costs exists [KFF, ASRM, claude_news] 4. **Legal/budgetary barriers?** — Congress controls appropriations; executive cannot mandate private insurers or fund universal IVF without legislation; anti-abortion conservatives within GOP actively oppose expansive IVF coverage [claude_news, KFF] 5. **Timeline/likelihood before Jan 20, 2029?** — ~2.5 years remain; administration has shown declining momentum (missed deadlines, incremental steps); no legislative vehicle advancing; trajectory points toward "No" [claude_news, congress.gov] # Key facts (high-confidence, factual) 1. [AJMC] Feb 18, 2025 EO directs recommendations only; creates no entitlement or funding mechanism 2. [Axios/ASRM] Oct 2025 deal covers 3 injectable drugs at 84% discount—not full cycle cost; typical IVF cycle costs $12,000–$25,000 total 3. [Prelude/KFF] TrumpRx drug discounts cover medications only; procedure, monitoring, lab costs remain unaddressed 4. [reproductivefreedom.house.gov] 90-day EO deadline (May 2025) missed with no follow-up policy announcement 5. [congress.gov] All 5 IVF-related bills in 119th Congress are Democrat-sponsored; none have advanced past committee referral 6. [GDELT/alternet] As of July 2026, IVF for military families specifically was killed in Congress despite Trump's promise # Cross-market signals - **Kalshi related**: No directly comparable market; "Will Trump bring back manufacturing?" at 17%—similar "ambitious campaign promise" structure - **Polymarket**: No active IVF markets found - **Sportsbook**: None found # Analyst opinions and speculation - KFF: Trump's October 2025 announcement "fell well short" of campaign promise [KFF] - ASRM: Evaluated initiative as insufficient; procedure costs remain prohibitive [ASRM] - Sen. Murray (D): Called original EO "a PR stunt" [claude_news] - Anti-abortion conservatives actively pushing back on IVF expansion, creating internal GOP resistance [claude_news] - CNN (May 2026): Cost reduction "still a long way off" [CNN] # Directional lean per outcome - **Yes (13%)**: Supporting — Trump has political motivation (birth rate agenda, campaign promise); ~2.5 years remain; employer mandate route possible; TrumpRx expanding. Opposing — No legislative vehicle; missed deadlines; all actions incremental; GOP internal opposition; "free" requires eliminating entire cycle cost, not just drug discounts; budget/appropriations constraints - **No (87%)**: Supporting — Pattern of incremental non-delivery; 90-day deadline missed; Congress not moving; anti-abortion wing resistance; "free" is a very high bar (full cycle, not partial discount); market drifting down # Gaps / unknowns - Whether any reconciliation bill language could include IVF mandate - Whether TRICARE/military IVF coverage could be interpreted as satisfying the resolution criterion - Whether TrumpRx expansion could ever cover full procedure costs - Definition edge: could a targeted VA/TRICARE program covering military families count as "eliminating the cost of at least one IVF cycle"? # Calibration anchors - **Kalshi anchor**: 13% YES (primary) - **Base rate**: Major campaign promises fully executed by US presidents: ~30–40%; but "free IVF" requires specific mechanism (appropriations/mandate) with no current legislative path - **Trajectory**: Price declined from ~17% to 13% over 63 days as deadlines were missed and actions fell short

1. Both forecasters under-weighted the TRICARE/military edge case flagged in the brief's "Gaps/unknowns" section: if a targeted VA or TRICARE program covering military families could satisfy the resolution criterion ("at least one IVF cycle"), this is a plausible executive pathway that requires no legislation and sidesteps anti-abortion conservatives—yet neither forecaster engaged seriously with it. 2. Both forecasters ignored the reconciliation bill wildcard noted in the brief; the current "Big Beautiful Bill" legislative environment means IVF provisions could theoretically be bundled into must-pass budget reconciliation, which would not require 60 Senate votes—a scenario with non-trivial probability given Trump's political motivation on birth rate/natalist agenda. 3. The base-rate anchor is misapplied: the brief cites ~30–40% for major campaign promises fully executed, but both forecasters lean below the already-below-market Kalshi price of 13% without adequately explaining why the specific resolution bar ("at least one cycle") is categorically harder than the average major promise—the "at least one" language could be satisfied by a narrow program (military, federal employees) rather than universal coverage. 4. Neither forecaster addressed the definition edge explicitly: the brief flags uncertainty about whether a targeted program (e.g., TRICARE) satisfies "eliminating the cost of at least one IVF cycle," and if adjudicators interpret this permissively, the effective Yes probability is meaningfully higher than if universal coverage is required—this ambiguity alone could justify staying closer to 13% rather than moving below it. 5. Both forecasters treat declining Kalshi momentum (17% → 13%) as confirmatory of their below-market lean, but 30-day volume averaging only 32 contracts means this price signal is extremely thin and should be discounted as a precision anchor, not treated as strong evidence of informed consensus.

13% (medium confidence)

Yes: 13% No: 87%

The critique makes a fair point: both forecasters drifted below the market anchor without strong justification, and the 'at least one cycle' language plus TRICARE/reconciliation pathways leave a real tail for Yes. I anchor at the Kalshi price of 13% rather than below it, since the thin volume and the permissive-definition ambiguity argue against overconfidence. The dominant evidence still favors No: all actions to date are incremental discounts, deadlines were missed, and no legislative vehicle is advancing.

Total pipeline time: 152.3s